Home > Product Storage and Stability Information > GLP-1 RAs (Glucagon-like Peptide-1 Receptor Agonists)
GLP-1 RAs
Explore other therapeutic areas
Ozempic® can be used as long as the product has not been exposed to temperatures below 36°F or above 86°F. If Ozempic® was exposed to non-refrigerated temperatures (any temperature above 46ºF), the product must be used or discarded within 56 days. Ozempic® should be inspected for changes such as precipitation, or change in color or clarity that may indicate a loss in potency.1
Recommended Storage Conditions for Ozempic®1
Before First Use
After First Use
Refrigerated (36°F - 46°F)
Room Temperature (59°F - 86°F)
Refrigerated (36°F - 46°F)
Until expiration date
56 days
56 days
Rybelsus® should be stored at room temperature 68° to 77°F (20° to 25°C); excursions are permitted to 59° to 86°F (15° to 30°C) [see USP Controlled Room Temperature]. Store and dispense in the original bottle. Store Rybelsus® tablets in the original bottle until use to protect tablets from moisture. Store Rybelsus® in a dry place away from moisture.2
Recommended Storage Conditions for RYBELSUS®2
Before First Use
After First Use
Room Temperature (68°F - 77°F)
Room Temperature (68°F - 77°F)
Until expiration date
Until expiration date
Saxenda® can be used as long as the product has not been exposed to temperatures below 36°F or above 86°F. If Saxenda® was exposed to non-refrigerated temperatures (any temperature above 46°F), the product must be used or discarded within 30 days. Saxenda® should be inspected for changes such as precipitation, or change in color or clarity that may indicate a loss in potency.3
Recommended Storage Conditions for Saxenda®3
Before First Use
After First Use
Refrigerated (36°F - 46°F)
Room Temperature (59°F - 86°F)
Refrigerated (36°F - 46°F)
Until expiration date
30 days
30 days
Victoza® can be used as long as the product has not been exposed to temperatures below 36°F or above 86°F. If unopened Victoza® was exposed to non-refrigerated temperatures (any temperature above 46ºF), the product must be used or discarded within 30 days. Victoza® should be inspected for changes such as precipitation, or change in color or clarity that may indicate a loss in potency.4
Recommended Storage Conditions for Victoza®4
Before First Use
After First Use
Refrigerated (36°F - 46°F)
Room Temperature (59°F - 86°F)
Refrigerated (36°F - 46°F)
Until expiration date
30 days
30 days
Wegovy® (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).5
Recommended Storage Conditions for Wegovy®5
Before First Use
After First Use
Refrigerated (36°F - 46°F)
Room Temperature (59°F - 86°F)
Refrigerated (36°F - 46°F)
Until expiration date
30 days
30 days
References
- Ozempic® Prescribing Information. Plainsboro, NJ: Novo Nordisk.
- RYBELSUS® Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.
- Saxenda® Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.
- Victoza® Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.
- Wegovy® Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.
Find more information
Speak to a medical representative
If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit here to contact us, or call 1-800-727-6500.
Search the Medical Information Database
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.
The purpose of this site is to provide relevant medical and scientific information about Novo Nordisk products and areas of therapeutic interest. Information about investigational products or investigational uses of approved products neither implies FDA approval for these products or uses, nor establishes the safety or efficacy of these products or uses. There is no guarantee that any investigational product or investigational use will receive FDA approval or become commercially available in the United States. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling.
This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only. Any products referenced on this site may have different labelling in different countries.
